Category: Treatment

Posted on

They are starting to figure out there is a cure.

As we have previously published months ago, for the record, hydroxychloroquine, sold under the trade name plaqenuil and a common antibiotic azithromycin, is stopping the infection dead in its tracks. be smart and get some. 

According to the International Journal of Antimicrobial Agents, they have found early evidence that the combination of hydroxycholorquine, a popular anti-malarial drug known under the trade name Plaqenuil, and antibiotic azithromycin (aka Zithromax or Azithrocin) could be especially effective in treating the COVID-19 coronavirus and reducing the duration of the virus in patients.

Posted on

ITS NO ACCIDENT YOU HAVE NOT BEEN TOLD OF THE CURE

Antiviral Res. 2008 Feb;77(2):150-2. Epub 2007 Nov 20.

Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK.

Kono M1, Tatsumi K, Imai AM, Saito K, Kuriyama T, Shirasawa H.

Abstract

The antiviral effects of chloroquine (CQ) on human coronavirus 229E (HCoV-229E) infection of human fetal lung cell line, L132 are reported. CQ significantly decreased the viral replication at concentrations lower than in clinical usage. We demonstrated that CQ affects the activation of p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK). Furthermore, p38 MAPK inhibitor, SB203580, inhibits CPE induced by HCoV-229E infection and viral replication. Our findings suggest that CQ affects the activation of MAPKs, involved in the replication of HCoV-229E.

Posted on

There is a CURE

Logo of aac

Prevention is a vaccine which we do not have. BUT we’ve got the next best thing and that is a cure. As usual we got there first and on these pages, before the pills were sucked up we told you what to get. If you were not listening that,s on you. i did my job!
Link to Publisher's site
Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice▿
Els Keyaerts, Sandra Li, Leen Vijgen, Evelien Rysman, Jannick Verbeeck, Marc Van Ranst,* and Piet Maes

Abstract

Until recently, human coronaviruses (HCoVs), such as HCoV strain OC43 (HCoV-OC43), were mainly known to cause 15 to 30% of mild upper respiratory tract infections. In recent years, the identification of new HCoVs, including severe acute respiratory syndrome coronavirus, revealed that HCoVs can be highly pathogenic and can cause more severe upper and lower respiratory tract infections, including bronchiolitis and pneumonia. To date, no specific antiviral drugs to prevent or treat HCoV infections are available. We demonstrate that chloroquine, a widely used drug with well-known antimalarial effects, inhibits HCoV-OC43 replication in HRT-18 cells, with a 50% effective concentration (± standard deviation) of 0.306 ± 0.0091 μM and a 50% cytotoxic concentration (± standard deviation) of 419 ± 192.5 μM, resulting in a selectivity index of 1,369. Further, we investigated whether chloroquine could prevent HCoV-OC43-induced death in newborn mice. Our results show that a lethal HCoV-OC43 infection in newborn C57BL/6 mice can be treated with chloroquine acquired transplacentally or via maternal milk. The highest survival rate (98.6%) of the pups was found when mother mice were treated daily with a concentration of 15 mg of chloroquine per kg of body weight. Survival rates declined in a dose-dependent manner, with 88% survival when treated with 5 mg/kg chloroquine and 13% survival when treated with 1 mg/kg chloroquine. Our results show that chloroquine can be highly effective against HCoV-OC43 infection in newborn mice and may be considered as a future drug against HCoVs.

Continue reading “There is a CURE”

Posted on

A French Professor Reveals Chloroquine Cures And Stops The Spread Of The Coronavirus

Professor Didier Raoult, director of the Mediterranean Institute of Infection, poses for a portrait in his office at La Timone hospital in Marseille, Southern France

An acclaimed research professor in France revealed successful results of a potential treatment for COVID-19, the coronavirus.

What’s going on:

    • Professor Didier Raoult, who works for the infection hospital l’Institut Hospitalo-Universitaire (IHU) Méditerranée Infection in Marseille, published a new video in which he explained that the COVID-19 patients who were treated “with the drug chloroquine had seen a rapid and effective speeding up of their healing process, and a sharp decrease in the amount of time they remained contagious.”
    • Chloroquine has previously been used to prevent and treat malaria.
    • The drug was offered to 24 patients, who were among the first 24 to become infected in France’s southeastern region.
    • Patients were given the drug for 10 days. Researchers monitored the patients since the drug can cause severe side effects.
    • Raoult said those who did not receive the drug were still contagious after six days. Those who tried the drug were only 25% contagious, though.